otub-1 Antibody

What is OTUB1 and why is it significant in cancer research?

OTUB1 is an OTU-family deubiquitinase that functions as a critical regulator of development, cancer, DNA damage response, and immune response . It has gained significant attention in cancer research due to its ability to stabilize key DNA repair proteins, such as MSH2, by preventing their ubiquitination and subsequent degradation . OTUB1 interacts with MSH2 through its deubiquitylation catalytic center, thereby maintaining genomic stability through preserving mismatch repair functionality . Studies have demonstrated that OTUB1 is potentially a biomarker for cancer etiology and therapy, as it influences cellular response to genotoxic agents like cisplatin and MNNG .

What are common applications for OTUB1 antibodies in research?

OTUB1 antibodies are primarily used in several key research applications:

• Western Blotting: For detecting OTUB1 protein expression levels in various cell types and tissues, with typical bands observed at approximately 31 kDa .

• Immunoprecipitation (IP): For studying protein-protein interactions between OTUB1 and its binding partners such as MSH2, PD-L1, and various components of DNA damage response pathways .

• Validating Knockdown or Knockout Models: OTUB1 antibodies are essential for confirming successful gene silencing in OTUB1 knockdown or knockout cell lines, which are frequently used to study OTUB1's functional roles .

• Studying Subcellular Localization: Some research indicates OTUB1 can relocalize under certain conditions, such as when it co-localizes with RIG-1 at mitochondrial membrane following RNA virus infection .

How do researchers distinguish between OTUB1's DUB-dependent and DUB-independent functions?

Distinguishing between OTUB1's deubiquitinating (DUB) activity and its non-catalytic E2-blocking function requires careful experimental design. Researchers typically employ the following strategies:

• Catalytic Mutants: Creating point mutations in OTUB1's catalytic site (particularly C91S or D88A mutants) allows researchers to create a version of OTUB1 that lacks deubiquitinating activity while maintaining its structure and E2-blocking capability . By comparing the effects of wild-type OTUB1 versus these catalytic mutants, researchers can determine which functions depend on DUB activity.

• Domain Mapping: Different proteins engage different regions of OTUB1. By mapping the interaction domains and creating truncation mutants, researchers can identify which protein interactions depend on which domains of OTUB1 . For example, the N-terminal region of OTUB1 is often important for E2 enzyme binding, while the OTU domain contains the catalytic site for deubiquitinating activity .

• Functional Assays: Monitoring different cellular outcomes can also help distinguish between mechanisms. For instance, Zhou et al. found that OTUB1's effect on T-cell response to IL-15 was maintained with a C91S catalytic mutant, indicating this function is independent of DUB activity .

What techniques are used to study OTUB1's effect on protein stability and ubiquitination?

Researchers employ several sophisticated techniques to investigate OTUB1's impact on protein stability and ubiquitination patterns:

• In vivo Ubiquitination Assays: These experiments typically involve co-expressing HA-tagged ubiquitin with the protein of interest (e.g., MSH2) in control and OTUB1-manipulated cells, followed by denatured immunoprecipitation to isolate the protein of interest and western blotting to detect ubiquitin modifications .

• Cycloheximide Chase Assays: To measure protein stability and half-life, researchers treat cells with cycloheximide (to block new protein synthesis) and then collect samples at various time points to track the degradation of specific proteins in the presence or absence of OTUB1 .

• Proximity Ligation Assays: These can be used to detect and visualize direct protein-protein interactions between OTUB1 and its substrates in situ.

• Mass Spectrometry Analysis: For identifying specific ubiquitination sites and ubiquitin chain topologies on OTUB1 substrates.

• Reconstitution Experiments: Restoring OTUB1 expression in OTUB1-knockdown cells to confirm that observed phenotypes are directly attributable to OTUB1 depletion rather than off-target effects .

How does OTUB1 influence immune responses and what implications does this have for cancer immunotherapy?

OTUB1 plays multifaceted roles in immune regulation with significant implications for cancer immunotherapy:

• PD-L1 Regulation: OTUB1 interacts with PD-L1 (an immune checkpoint molecule) and removes K48-linked ubiquitin chains, thereby stabilizing PD-L1 on cancer cells . Consequently, OTUB1 knockdown decreases PD-L1 protein levels in cancer cells and increases tumor sensitivity to T-cell mediated cytotoxicity .

• CD8+ T Cell Regulation: OTUB1 has been shown to repress CD8+ T cell activation. Loss of OTUB1 in T-cells causes aberrant activation of CD8+ T cells and enhances their anticancer immunity . This occurs because OTUB1 can redistribute to the plasma membrane following IL-15 stimulation, where it represses the ubiquitination-dependent activation of AKT, a critical pathway for T-cell activity .

• Innate Immunity Regulation: OTUB1 activates RIG-I (a pattern recognition receptor that detects viral RNA) at mitochondria through both DUB activity and E2-blocking activity, thereby influencing innate immune responses to viral infections .

What are the best practices for validating OTUB1 antibody specificity?

Validating antibody specificity is crucial for ensuring reliable experimental results. For OTUB1 antibodies, researchers should:

• Use Knockout/Knockdown Controls: Compare antibody signal between wild-type cells and OTUB1 knockout or knockdown cells. A specific antibody will show significantly reduced or absent signal in the knockout/knockdown samples, as demonstrated with ab175200 antibody testing on OTUB1 knockout HEK-293T cells .

• Test Multiple Cell Lines/Tissues: Verify consistent detection of the correct molecular weight band (approximately 31 kDa for OTUB1) across different sample types .

• Include Loading Controls: Always include appropriate loading controls (e.g., vinculin, GAPDH) to normalize protein loading across samples .

• Use Multiple Antibodies: When possible, validate findings with multiple antibodies targeting different epitopes of OTUB1.

• Preabsorption Tests: For immunohistochemistry applications, preincubate the antibody with purified OTUB1 protein before staining to demonstrate that specific binding is blocked.

What are common pitfalls in OTUB1 immunoprecipitation experiments and how can they be addressed?

Immunoprecipitation of OTUB1 can be challenging due to several factors:

• Weak Interactions: OTUB1 interactions with binding partners like MSH2 can be relatively weak, making them difficult to capture . To address this:

  • Use gentler lysis buffers with lower detergent concentrations

  • Include protease inhibitors and deubiquitinase inhibitors in all buffers

  • Consider crosslinking approaches for transient interactions

  • Optimize antibody concentrations and incubation times/temperatures

• Non-specific Binding: Always include appropriate negative controls, such as isotype control antibodies or IgG, as demonstrated in IP experiments with HeLa cells .

• Detection Issues: For detecting OTUB1 in western blots following IP, specialized detection reagents like VeriBlot for IP Detection Reagent may be necessary to avoid detection of IP antibody heavy and light chains .

• Buffer Optimization: The lysis buffer composition (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% NP-40) can significantly impact IP efficiency and should be optimized for specific experimental contexts .

• Pre-clearing Lysates: Pre-clear cell lysates with protein A/G beads for 2 hours before performing the IP to reduce non-specific binding .

How can researchers effectively establish and validate OTUB1 knockdown or knockout cell models?

Creating reliable OTUB1-deficient cell models is essential for studying its functions:

• Choice of Knockdown/Knockout Approach:

  • For transient studies, siRNA or shRNA approaches can be effective

  • For stable knockdown, lentiviral delivery of shRNA is recommended, as described in the study using pLKO.1 vector

  • For complete knockout, CRISPR-Cas9 approaches provide the most definitive results

• Viral Packaging and Transduction Protocol:

  • Transfect HEK293T cells with target plasmid and packaging plasmids (psPAX2 and pMD2.G) at a 4:3:1 ratio

  • Collect viral supernatants after 72 hours and filter through a 0.45-nm filter

  • Add viruses to target cells and incubate for 24 hours

  • Replace with fresh medium for another 24 hours

  • Select transduced cells with appropriate antibiotic (e.g., 10 μg/ml puromycin) for approximately 2 weeks

• Validation of Gene Editing:

  • Confirm knockdown/knockout efficiency by western blotting using validated anti-OTUB1 antibodies

  • Consider measuring OTUB1 mRNA levels by qRT-PCR

  • For knockout cell lines, sequence the targeted genomic region to confirm mutations

• Rescue Experiments:

  • Create OTUB1-restored cell lines by re-introducing wild-type or mutant OTUB1 (e.g., using PLVX-IRES-ZsGreen1 vector)

  • These rescue experiments are critical to rule out potential off-target effects in knockdown cells and can confirm that observed phenotypes are specifically due to OTUB1 depletion